Lumanity today announced the acquisition of Innovative Edge (“IE”), a leading provider of pharmaceutical product launch services.
The highly complementary addition of IE is fully aligned with Lumanity’s commitment to partnering with life sciences companies around the world to propel commercialization forward. With the addition of IE, Lumanity offers end-to-end launch capabilities that combines commercialization strategy with launch implementation.
IE partners with world-leading biopharma companies – from Top 20 pharmaceutical manufacturers to fast-growing biotechnology companies – to optimize and accelerate their global, regional, and local product launches - the company has supported hundreds of product launches, helping to chart, implement, and monitor the key elements required for a successful launch.
The acquisition of IE strengthens an already unique and diverse collection of deeply experienced industry pioneers, data luminaries, subject expert matters, and proven problem solvers with advanced clinical, scientific, and functional capabilities.
Steve Marsh, Founder and CEO of IE, said, “We are thrilled to join this exciting and rapidly growing organization. Our combined capabilities will enable us to build comprehensive launch support programs that work across functions and geographies, and that stretch from early strategy through to tactical implementation”.
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.